A nano-carrier-based drug delivery system developed under the Science and Technology Union Science and Technology Division, Science for Equity Empowerment and Development (SEED) Division, can facilitate the psoriasis treatment and many other skin conditions. It is aimed to reduce the frequency of skin application to once a day as compared to three times a day in case of a conventional dosage of medicine. As per the DST website, the program resulted in a decrease in treatment costs and time to half of the available consumer gel. According to Ankita Daddiwal, a researcher who completed the research under the guidance of her Professor RK Narang, the nanocarrier supplies a chemical called clobetasol propionate, a corticosteroid used to treat different types of skin conditions, can increase the solubility of the chemical, improve storage stability, improve permeability, reduce adverse effects, extend half-life, and tissue-targeted delivery.

By enhancing its penetration through infected skin, these enhanced properties have increased the effectiveness of clobetasol propionate. The Psoriasis Severity Index (PASI) is used to measure the severity of psoriasis. The developed system showed a decline of 85% in the average PASI score compared to the marketed formulation, which showed a decline in the average PASI score of only 50 percent. This is a big leap in the Psoriasis treatment

As per the DST website, the system also resulted in “40 percent more skin retention and 80 percent decrease in systemic circulation drug availability compared to marketed gel.” Psoriasis is an autoimmune disease that affects the skin by activating the cellular immune system inappropriately. Psoriasis affects 125 million people worldwide, according to the National Psoriasis Foundation.